The UK government has unveiled an ambitious strategy aimed at accelerating the phase-out of animal testing in favour of novel alternative methods. Backed by significant funding and clear regulatory commitments, the roadmap supports research into organ-on-a-chip systems, AI-led predictive models, and 3D biologically-printed tissues.
This initiative aligns powerfully with the mission of MicroTex, to develop micro and nano scale delivery and sensing platforms capable of assessing therapeutic agents in humans. With our work focused on technologies like robotic delivery systems, microsensors and microneedle patches, MicroTex is well positioned to support, and benefit from, the shift towards human-based alternatives.
In particular, the government’s emphasis on streamlining regulatory pathways mirrors our own translational goals, as we aim to move technologies from lab-based prototypes into clinical settings with patient-centred outcomes. The roadmap’s promise of increased funding for non-animal methods offers new collaborative and translational opportunities for MicroTex, broadening our potential partnerships across industry, academia, and regulatory networks.
By embedding our technologies within this emerging framework, MicroTex not only strengthens its own scientific and translational trajectory, but also contributes to a wider shift in how therapies are developed, more efficiently, ethically, and with greater relevance to human health.
Find out more and read the press release here: GOV.UK